Which has preferable valuation and earnings, PHVS or QGEN?

Qiagen has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Qiagen $2.09B 3.62 $424.88M $1.91 19.21

Is PHVS or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Pharvaris' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Qiagen 19.16% 14.40% 8.40%

Does the media favor PHVS or QGEN?

In the previous week, Qiagen had 5 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Qiagen and 1 mentions for Pharvaris. Qiagen's average media sentiment score of 0.29 beat Pharvaris' score of 0.00 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, PCVX or PHVS?

Pharvaris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Pharvaris N/A N/A -$198.79M -$3.18 N/A

Is PCVX or PHVS more profitable?

Vaxcyte's return on equity of -32.51% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Pharvaris N/A -67.56% -61.13%

Does the media favor PCVX or PHVS?

In the previous week, Vaxcyte had 5 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Vaxcyte and 1 mentions for Pharvaris. Vaxcyte's average media sentiment score of 0.21 beat Pharvaris' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, IMVT or PHVS?

Immunovant is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Pharvaris N/A N/A -$198.79M -$3.18 N/A

Is IMVT or PHVS more profitable?

Immunovant's return on equity of -65.66% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Pharvaris N/A -67.56% -61.13%

Does the media favor IMVT or PHVS?

In the previous week, Immunovant had 3 more articles in the media than Pharvaris. MarketBeat recorded 4 mentions for Immunovant and 1 mentions for Pharvaris. Immunovant's average media sentiment score of 0.41 beat Pharvaris' score of 0.00 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, PHVS or LNTH?

Lantheus has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Lantheus $1.54B 4.26 $233.56M $4.15 24.33

Is PHVS or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Pharvaris' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Lantheus 18.05% 29.32% 15.00%

Does the media prefer PHVS or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Pharvaris. MarketBeat recorded 4 mentions for Lantheus and 1 mentions for Pharvaris. Lantheus' average media sentiment score of 0.20 beat Pharvaris' score of 0.00 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PHVS or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 2 mentions for Kymera Therapeutics and 1 mentions for Pharvaris. Kymera Therapeutics' average media sentiment score of 1.05 beat Pharvaris' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pharvaris (PHVS) Competitors

$31.09 -0.54 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$31.08 -0.01 (-0.03%)

As of 04:44 PM Eastern

Compare

PHVS vs. QGEN, PCVX, IMVT, LNTH, and KYMR

Should you buy Pharvaris stock or one of its competitors? MarketBeat compares Pharvaris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharvaris include Qiagen (QGEN), Vaxcyte (PCVX), Immunovant (IMVT), Lantheus (LNTH), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Pharvaris compare to Qiagen?

Pharvaris (NASDAQ:PHVS) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Qiagen had 5 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Qiagen and 1 mentions for Pharvaris. Qiagen's average media sentiment score of 0.29 beat Pharvaris' score of 0.00 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Qiagen	$2.09B	3.62	$424.88M	$1.91	19.21

70.0% of Qiagen shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Qiagen has a net margin of 19.16% compared to Pharvaris' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Qiagen	19.16%	14.40%	8.40%

Pharvaris has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Pharvaris currently has a consensus price target of $49.18, suggesting a potential upside of 58.19%. Qiagen has a consensus price target of $44.98, suggesting a potential upside of 22.61%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Summary

Qiagen beats Pharvaris on 12 of the 16 factors compared between the two stocks.

How does Pharvaris compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Pharvaris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Vaxcyte has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market.

Vaxcyte currently has a consensus target price of $86.00, suggesting a potential upside of 81.59%. Pharvaris has a consensus target price of $49.18, suggesting a potential upside of 58.19%. Given Vaxcyte's higher probable upside, equities analysts plainly believe Vaxcyte is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Vaxcyte's return on equity of -32.51% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Pharvaris	N/A	-67.56%	-61.13%

In the previous week, Vaxcyte had 5 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Vaxcyte and 1 mentions for Pharvaris. Vaxcyte's average media sentiment score of 0.21 beat Pharvaris' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.8% of Vaxcyte shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Vaxcyte beats Pharvaris on 8 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market.

47.1% of Immunovant shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunovant's return on equity of -65.66% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Pharvaris	N/A	-67.56%	-61.13%

Immunovant is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

In the previous week, Immunovant had 3 more articles in the media than Pharvaris. MarketBeat recorded 4 mentions for Immunovant and 1 mentions for Pharvaris. Immunovant's average media sentiment score of 0.41 beat Pharvaris' score of 0.00 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant currently has a consensus price target of $37.33, suggesting a potential upside of 20.00%. Pharvaris has a consensus price target of $49.18, suggesting a potential upside of 58.19%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Immunovant beats Pharvaris on 7 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Lantheus?

Pharvaris (NASDAQ:PHVS) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Lantheus has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Lantheus	$1.54B	4.26	$233.56M	$4.15	24.33

In the previous week, Lantheus had 3 more articles in the media than Pharvaris. MarketBeat recorded 4 mentions for Lantheus and 1 mentions for Pharvaris. Lantheus' average media sentiment score of 0.20 beat Pharvaris' score of 0.00 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 58.19%. Lantheus has a consensus target price of $101.86, indicating a potential upside of 0.87%. Given Pharvaris' higher possible upside, equities analysts plainly believe Pharvaris is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.1% of Lantheus shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Pharvaris' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Lantheus	18.05%	29.32%	15.00%

Pharvaris has a beta of -2.35, indicating that its stock price is 335% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market.

Summary

Lantheus beats Pharvaris on 12 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Kymera Therapeutics?

Pharvaris (NASDAQ:PHVS) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Pharvaris currently has a consensus target price of $49.18, suggesting a potential upside of 58.19%. Kymera Therapeutics has a consensus target price of $118.10, suggesting a potential upside of 59.31%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Pharvaris has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 2 mentions for Kymera Therapeutics and 1 mentions for Pharvaris. Kymera Therapeutics' average media sentiment score of 1.05 beat Pharvaris' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Kymera Therapeutics	$39.21M	155.52	-$311.35M	-$3.57	N/A

Pharvaris has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Summary

Kymera Therapeutics beats Pharvaris on 10 of the 14 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export

Metric	Pharvaris	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.07B	$3.36B	$6.49B	$12.46B
Dividend Yield	N/A	2.31%	2.67%	5.34%
P/E Ratio	-9.78	10.39	20.30	22.08
Price / Sales	N/A	298.63	517.33	112.57
Price / Cash	N/A	114.83	42.35	57.17
Price / Book	6.60	6.51	9.73	6.37
Net Income	-$198.79M	$24.09M	$3.56B	$337.36M
7 Day Performance	3.08%	-6.98%	-3.19%	-3.07%
1 Month Performance	3.56%	-3.57%	-0.11%	0.37%
1 Year Performance	93.71%	42.44%	25.29%	27.87%

Pharvaris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHVS Pharvaris	3.5121 of 5 stars	$31.09 -1.7%	$49.18 +58.2%	+90.3%	$2.07B	N/A	N/A	30	Short Interest Decrease High Trading Volume
QGEN Qiagen	4.1639 of 5 stars	$35.72 -1.2%	$44.98 +25.9%	-22.1%	$7.54B	$2.10B	18.79	5,654
PCVX Vaxcyte	2.8056 of 5 stars	$47.39 -3.1%	$86.00 +81.5%	+44.1%	$7.42B	N/A	N/A	160	Insider Trade
IMVT Immunovant	2.2243 of 5 stars	$30.87 -6.0%	$37.33 +20.9%	+113.0%	$6.75B	N/A	N/A	120
LNTH Lantheus	2.0205 of 5 stars	$96.37 -0.8%	$101.86 +5.7%	+29.1%	$6.47B	$1.55B	23.77	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHVS) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Competitors